Abstract:Background: Systemic sclerosis (SSc) is a chronic and systemic autoimmune disease marked by the skin and visceral fibrosis. Metabolic alterations have been found in SSc patients; however, serum metabolomic profiling has not been thoroughly conducted. Our study aimed to identify alterations in the metabolic profile in both SSc patients before and during treatment, as well as in mouse models of fibrosis. Furthermore, the associations between metabolites and clinical parameters and disease progression were explored. Methods: High-performance liquid chromatography quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)/MS was performed in the serum of 326 human samples and 33 mouse samples. Human samples were collected from 142 healthy controls (HC), 127 newly diagnosed SSc patients without treatment (SSc baseline), and 57 treated SSc patients (SSc treatment). Mouse serum samples were collected from 11 control mice (NaCl), 11 mice with bleomycin (BLM)-induced fibrosis and 11 mice with hypochlorous acid (HOCl)-induced fibrosis. Both univariate analysis and multivariate analysis (orthogonal partial least-squares discriminate analysis (OPLS-DA)) were conducted to unravel differently expressed metabolites. KEGG pathway enrichment analysis was performed to characterize the dysregulated metabolic pathways in SSc. Associations between metabolites and clinical parameters of SSc patients were identified by Pearson's or Spearman's correlation analysis. Machine learning (ML) algorithms were applied to identify the important metabolites that have the potential to predict the progression of skin fibrosis. Results: The newly diagnosed SSc patients without treatment showed a unique serum metabolic profile compared to HC. Treatment partially corrected the metabolic changes in SSc. Some metabolites (phloretin 2'-O-glucuronide, retinoyl b-glucuronide, all-trans-retinoic acid, and betaine) and metabolic pathways (starch and sucrose metabolism, proline metabolism, androgen and estrogen metabolism, and tryptophan metabolism) were dysregulated in new-onset SSc, but restored upon treatment. Some metabolic changes were associated with treatment response in SSc patients. Metabolic changes observed in SSc patients were mimicked in murine models of SSc, indicating that they may reflect general metabolic changes associated with fibrotic tissue remodeling. Several metabolic changes were associated with SSc clinical parameters. The levels of allysine and all-trans-retinoic acid were negatively correlated, while D-glucuronic acid and hexanoyl carnitine were positively correlated with modified Rodnan skin score (mRSS). In addition, a panel of metabolites including proline betaine, phloretin 2'-O-glucuronide, gamma-linolenic acid and L-cystathionine were associated with the presence of interstitial lung disease (ILD) in SSc. Specific metabolites identified by ML algorithms, such as medicagenic acid 3-O-b-D-glucuronide, 4'-O-methyl-(-)-epicatechin-3'-O-beta-glucuronide, valproic acid glucuronide, have the potential to predict the progression of skin fibrosis. Conclusions: Serum of SSc patients demonstrates profound metabolic changes. Treatment partially restored the metabolic changes in SSc. Moreover, certain metabolic changes were associated with clinical manifestations such as skin fibrosis and ILD, and could predict the progression of skin fibrosis.

Diagnostic performance of distinct metabolic features in the plasma of patients with silicosis

Exosomal proteomics and cytokine analysis distinguish silicosis cases from controls

Exploration study on serum metabolic profiles of Chinese male patients with artificial stone silicosis, silicosis, and coal worker's pneumoconiosis

Combined application of multiple biomarkers for early auxiliary diagnosis of silicosis

The value of single biomarkers in the diagnosis of silicosis: A meta-analysis

Screening of Serum Biomarkers and Establishment of a Decision Tree in Silica-Exposed Populations by Surface-Enhanced Laser Desorption Ionization Time-of-fly Mass Spectrometry.

Lipid characteristics of lung tissue in silicosis rat model were studied based on lipid metabolomics

CC-Chemokine Ligand 18, CXC Motif Chemokine 13, and Osteopontin as Biomarkers of Silicosis and Asbestosis: A Case-Control Study

Integrating routine blood biomarkers and artificial intelligence for supporting diagnosis of silicosis in engineered stone workers

Integrated mRNA and microRNA profiling in lung tissue and blood from human silicosis

A Differential Protein Study on Bronchoalveolar Lavage Fluid at Different Stages of Silicosis

Exploratory study on noninvasive biomarker of silicosis in exhaled breath by solid-phase microextraction–gas chromatography–mass spectrometry analysis

Biomonitoring Exposure and Early Diagnosis in Silicosis: A Comprehensive Review of the Current Literature

Non-invasive Detection of Silicosis Based on Array Sensing and Pattern Recognition

The study of metabolism and metabolomics in a mouse model of silica pulmonary fibrosis based on UHPLC-QE-MS

Biomarkers related to silicosis and pulmonary function in individuals exposed to silica

Inflammatory indices obtained from routine blood tests show an inflammatory state associated with disease progression in engineered stone silicosis patients

Proteomic profiling differences in serum from silicosis and chronic bronchitis patients: a comparative analysis

Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype

Down‐Regulation of miR‐19a as a Biomarker for Early Detection of Silicosis